http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102363043-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2019-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102363043-B1 |
| titleOfInvention | Pharmaceutical composition for preventing or treating cancer comprising a PI3 kinase inhibitor and a cytotoxic anticancer agent |
| abstract | The present invention provides a pharmaceutical composition for preventing or treating cancer comprising a PI3 kinase inhibitor and a cytotoxic anticancer agent. The composition according to the present invention exhibits a superior cancer treatment effect compared to the case of administering the compound of Formula 1 or the cytotoxic anticancer agent used as a PI3 kinase inhibitor alone. Therefore, the composition of the present invention can be usefully applied to the prevention, treatment or improvement of cancer. |
| priorityDate | 2018-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 124.